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ABSTRACT 
 
Extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica serotype 
Isangi has emerged as a common Salmonella serotype affecting mainly children in 
hospitals throughout South Africa.  Between 2000 and 2002, 279 S. Isangi isolates from 
single infection episodes were referred from 21 hospitals in 5 provinces to the Enteric 
Diseases Reference Unit of the National Institute for Communicable Diseases of South 
Africa.  All isolates were subjected to antibiotic susceptibility testing and three disk-
diffusion methods confirmed ESBL-production in 273 isolates. PCR and nucleotide 
sequencing of 101 isolates identified TEM-1 (2%), TEM-63 (91%), a novel TEM-131 
(7%), and SHV-5 (2%), but CTX-M was not found.  Plasmid profiling produced types 
with 1 to 6 plasmids, 7.4kb to 166kb in size, which were neither serotype nor ESBL-
type specific. Pulsed-field gel electrophoresis revealed four major clusters while sub-
clusters with identical, or near identical banding patterns suggested extensive intra-
hospital transmission and clonal spread between hospitals and provinces in South 
Africa.      
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